JP2016502551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502551A5 JP2016502551A5 JP2015545783A JP2015545783A JP2016502551A5 JP 2016502551 A5 JP2016502551 A5 JP 2016502551A5 JP 2015545783 A JP2015545783 A JP 2015545783A JP 2015545783 A JP2015545783 A JP 2015545783A JP 2016502551 A5 JP2016502551 A5 JP 2016502551A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- repeat
- toxin
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 25
- 230000002163 immunogen Effects 0.000 claims 15
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 8
- 101710182223 Toxin B Proteins 0.000 claims 8
- 101710182532 Toxin a Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 241000193163 Clostridioides difficile Species 0.000 claims 5
- 229930182558 Sterol Natural products 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 3
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1221875.6 | 2012-12-05 | ||
| GB201221875 | 2012-12-05 | ||
| PCT/EP2013/075405 WO2014086787A1 (en) | 2012-12-05 | 2013-12-03 | Immunogenic composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020900A Division JP6626521B2 (ja) | 2012-12-05 | 2018-02-08 | 免疫原性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502551A JP2016502551A (ja) | 2016-01-28 |
| JP2016502551A5 true JP2016502551A5 (https=) | 2017-01-19 |
| JP6290918B2 JP6290918B2 (ja) | 2018-03-07 |
Family
ID=49724573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545783A Active JP6290918B2 (ja) | 2012-12-05 | 2013-12-03 | 免疫原性組成物 |
| JP2018020900A Active JP6626521B2 (ja) | 2012-12-05 | 2018-02-08 | 免疫原性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020900A Active JP6626521B2 (ja) | 2012-12-05 | 2018-02-08 | 免疫原性組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9694064B2 (https=) |
| EP (2) | EP3513806B1 (https=) |
| JP (2) | JP6290918B2 (https=) |
| CN (2) | CN112807422A (https=) |
| AR (1) | AR093712A1 (https=) |
| AU (1) | AU2013354186A1 (https=) |
| BR (1) | BR112015012841B1 (https=) |
| CA (1) | CA2893435C (https=) |
| CY (1) | CY1121560T1 (https=) |
| DK (2) | DK3513806T5 (https=) |
| ES (2) | ES2939307T3 (https=) |
| FI (1) | FI3513806T3 (https=) |
| HR (2) | HRP20190711T1 (https=) |
| HU (2) | HUE043091T2 (https=) |
| LT (2) | LT2928489T (https=) |
| PL (2) | PL2928489T3 (https=) |
| PT (2) | PT3513806T (https=) |
| SG (1) | SG11201503861UA (https=) |
| SI (2) | SI3513806T1 (https=) |
| TR (1) | TR201905272T4 (https=) |
| WO (1) | WO2014086787A1 (https=) |
| ZA (1) | ZA201503927B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110072A1 (es) * | 2005-06-27 | 2011-02-04 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014086787A1 (en) * | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| BE1022949B1 (fr) * | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
| SG11201700089QA (en) * | 2014-07-25 | 2017-02-27 | Biosynth Srl | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
| CA2976976C (en) | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3433264A4 (en) | 2016-03-21 | 2019-08-28 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR INHIBITING WNT SIGNALING |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2019010948A (es) * | 2017-03-15 | 2020-01-09 | Novavax Inc | Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile. |
| CN107397956A (zh) * | 2017-08-08 | 2017-11-28 | 南开大学 | 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用 |
| WO2019143552A1 (en) | 2018-01-16 | 2019-07-25 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
| GB201804092D0 (en) * | 2018-03-14 | 2018-04-25 | Imperial Innovations Ltd | Methods and compositions |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| EP3972638A4 (en) * | 2019-05-21 | 2023-09-13 | The Regents Of The University Of California | VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| AU2023393199A1 (en) * | 2022-12-13 | 2025-05-29 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
| EP4658302A1 (en) | 2023-02-02 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| EP0362278A4 (en) | 1987-06-05 | 1990-05-14 | Us Health | Autocrine motility factors in cancer diagnosis and management. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE115862T1 (de) | 1989-02-04 | 1995-01-15 | Akzo Nobel Nv | Tocole als impfstoffadjuvans. |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US5776468A (en) | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| NZ295998A (en) | 1994-10-24 | 1999-10-28 | Ophidian Pharm Inc | Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP2305303A3 (en) | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
| GB0525321D0 (en) * | 2005-12-13 | 2006-01-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EA015817B1 (ru) * | 2006-10-12 | 2011-12-30 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде" |
| GB0711858D0 (en) * | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
| PL2198007T3 (pl) | 2007-09-14 | 2018-03-30 | Sanofi Pasteur Biologics, Llc | Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile |
| ES2553113T3 (es) * | 2008-04-16 | 2015-12-04 | Glaxosmithkline Biologicals S.A. | Vacuna |
| CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| PL2753352T5 (pl) * | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| HUE037126T2 (hu) * | 2011-05-27 | 2018-08-28 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| WO2014086787A1 (en) * | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
-
2013
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en not_active Ceased
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
- 2013-12-03 CA CA2893435A patent/CA2893435C/en active Active
- 2013-12-03 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
- 2013-12-03 DK DK19159001.7T patent/DK3513806T5/da active
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/en active
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
-
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
-
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
-
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
-
2019
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016502551A5 (https=) | ||
| HRP20190711T1 (hr) | Imunogeni pripravak | |
| JP2012176978A5 (https=) | ||
| WO2007095976A3 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
| JP2016513638A5 (https=) | ||
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| RU2015142996A (ru) | Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа | |
| NZ612315A (en) | Compositions for immunising against staphylococcus aureus | |
| JP2021514387A5 (https=) | ||
| PE20100658A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| JP2009191078A5 (https=) | ||
| JP2014530010A5 (https=) | ||
| JP2012102105A5 (https=) | ||
| JP2008539187A5 (https=) | ||
| JP2014521605A5 (https=) | ||
| IL276661B2 (en) | Immunogenic preparation containing staphylococcal antigens | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| JP2018505882A5 (https=) | ||
| JP2014508734A5 (https=) | ||
| CA2765511C (en) | Nanoemulsion vaccines | |
| JP2017508006A5 (https=) | ||
| AR088907A1 (es) | Vacuna |